Recent Updates — ONCO
The Board of Directors approved a one-for-ten (1:10) reverse stock split, which combined with the prior 1:10 split effective May 21, results in an aggregate one-for-one hundred (1:100) reduction. The transaction is expected to become effective at 12:01 a.m. ET on November 6, 2026, reducing outstanding shares from approximately 5.9 million to roughly 589,000. Fractional shares will be cashed out based on the closing price on November 5. Onconetix is a commercial-stage biotechnology company focused on oncology solutions and owns the Proclarix prostate cancer diagnostic test.
On October 22, 2026, Onconetix advanced an additional $500,000 to Realbotix pursuant to a Grid Promissory Note dated September 11, 2026. This brings the total outstanding principal under the note to $3.0 million against a maximum aggregate amount of $5.0 million, following a prior $2.5 million advance on September 11. The terms of the note remain unchanged. Onconetix operates in the biotechnology sector.
On September 11, 2026, Onconetix entered into a Grid Promissory Note with Realbotix to provide up to $5.0 million in loans, advancing an initial $2.5 million for general corporate purposes. The unsecured facility bears no interest until the earlier of the closing or termination of the pending acquisition defined by the February 11, 2026 Share Exchange Agreement; if terminated, interest accrues at 12% per annum. Upon successful closing, the note is automatically cancelled and discharged, reducing the required net cash at closing by $500,000 plus the outstanding principal balance. Realbotix Corp. guarantees these obligations. Onconetix operates in the biotechnology industry, focusing on oncology solutions.
On July 28, 2026, Onconetix, Inc. entered into a securities purchase agreement to issue and sell 37,812 shares of Series F convertible preferred stock for an aggregate price of $30,249,600. The preferred stock has a stated value of $1,000 per share and converts at an initial price of $0.9767 per common share. Concurrently, the company established a committed equity line of credit allowing up to $750 million in future common stock issuances, subject to Nasdaq limits. A $30 million commitment fee was paid toward the PIPE purchase price. Onconetix is a clinical-stage biotechnology company focused on developing cancer immunotherapies.